- Chemours reported third quarter 2026 sales of US$1,540 million and net income of US$196 million, with basic and diluted EPS from continuing operations of US$1.29. The board affirmed a quarterly dividend of US$0.0875 per share payable in December.
- Across the first nine months of 2026, Chemours recorded sales of US$4,512 million and a reduced loss of US$107 million, indicating that profitability in the latest quarter contrasts with earlier year-to-date pressure on earnings and cash generation.
- The focus now turns to how Chemours’ investment narrative could be affected by the sharp year-on-year improvement in third quarter net income.
Scan beyond Chemours’ rebound and line up other earnings driven opportunities with the hand picked 34 high quality undervalued stocks that currently pair resilient cash flows with sturdier balance sheets.
Chemours Investment Narrative Recap
To own Chemours, you need to be comfortable with a chemicals business that leans heavily on refrigerants, titanium dioxide and advanced materials, while still working through legal and balance sheet pressure. The third quarter swing to a US$196 million profit highlights what the portfolio can earn in a more supportive operating patch, but year to date losses show that recovery is not yet consistent.
The near term bull case rests on execution in Thermal & Specialized Solutions as refrigerant destocking and regulatory shifts play through, and on mix improvement in higher value Performance Solutions. The biggest risk remains PFAS related liabilities and any cash strain from debt and interest coverage, which could limit how much of any earnings rebound reaches shareholders.
Among the recent announcements, the most directly relevant development is the third quarter earnings release on 2 November 2026. Chemours reported sales of US$1,540 million versus US$1,495 million a year earlier and net income of US$196 million versus US$46 million. Basic and diluted EPS from continuing operations were US$1.29, compared with US$0.31 in the same quarter last year.
That step up in profitability sits against nine month sales of US$4,512 million and a net loss of US$107 million, so it matters for how you view the near term catalyst. The analysis focuses on whether Chemours can keep quarterly results closer to the third quarter run rate while managing PFAS exposure, refrigerant regulation risk and debt costs, because this would affect how durable the earnings story looks relative to the year to date headline loss.
Chemours' current earnings are a loss of US$304.0 million, with analysts forecasting a revenue growth rate of 4.3% per year and consensus earnings of US$268.4 million by 2029. This implies an earnings swing of about US$572 million into profit on that timeline.
Uncover why Chemours' fair value indicates a 28% potential upside to its current price. This may represent a discount that Chemours investors could see close sooner than expected.
Exploring Other Perspectives
Bullish analysts focus on Chemours as an AI and data center coolant winner, which is a very different story from the PFAS and refrigerant destocking worries in the baseline case. Before this earnings release, the most optimistic forecasts were revenue of about US$7.1b and earnings of roughly US$1.7b by 2029. Those projections describe a more positive path than consensus. Use this new quarterly beat as a prompt to compare those contrasting views and decide which assumptions you find realistic.
Explore 4 other Chemours fair value estimates, including one that suggests as much as 231% upside from the current price.
Form Your Own Verdict
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Chemours research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.
- See our latest analysis for Chemours. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Chemours' overall financial health at a glance.
Looking For More Ideas Beyond Chemours?
If Chemours is only one piece of the picture for you, it can help to line it up against other businesses with different risk and income profiles. Use the Simply Wall St Screener to compare Chemours' setup with a wider watchlist and pressure test whether it really earns a spot in your portfolio.
- If you care most about steady income, scan for dependable payers using our 4 dividend fortresses that combine higher yields with detailed balance sheet checks.
- If resilience and capital preservation matter more to you right now, filter for companies on the 29 resilient stocks with low risk scores that pair lower risk scores with more robust fundamentals.
- If you are hunting for mispriced quality, sort through the 19 high quality undiscovered gems and see which lesser known stocks currently line up with your return and risk preferences.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com